Annovis Awarded $1.7 Million NIH Grant for ANVS401 Chronic Toxicology Studies
BERWYN, PA — Annovis Bio Inc. (NYSE: ANVS), a clinical-stage drug platform company addressing Alzheimer’s (AD) , Parkinson’s (PD) and other neurodegenerative diseases, was awarded a $1.7 million grant from …
Read More